AGLE 325
Alternative Names: AGLE-325Latest Information Update: 26 Dec 2023
At a glance
- Originator Aeglea Biotherapeutics
- Developer Spyre Therapeutics
- Class Enzymes; Recombinant proteins; Urologics
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Cystinuria